Hiroshi Yoshida

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6017850/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Genetic features of endometrioid-type endometrial carcinoma arising in uterine adenomyosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 117-123.	2.8	2
2	Establishment and Characterization of NCC-PMP1-C1: A Novel Patient-Derived Cell Line of Metastatic Pseudomyxoma Peritonei. Journal of Personalized Medicine, 2022, 12, 258.	2.5	2
3	Bartholin's glands commonly express <scp>NKX3</scp> .1: reconsideration of "prostatic differentiation―in gynaecological pathology. Histopathology, 2022, 80, 1013-1015.	2.9	2
4	Aberrant Activation of Cell-Cycle–Related Kinases and the Potential Therapeutic Impact of PLK1 or CHEK1 Inhibition in Uterine Leiomyosarcoma. Clinical Cancer Research, 2022, 28, 2147-2159.	7.0	14
5	Clinical impact of genetic alterations of <i>CTNNB1</i> in patients with grade 3 endometrial endometrioid carcinoma. Cancer Science, 2022, 113, 1712-1721.	3.9	3
6	Discrepancies in pathological diagnosis of endometrial stromal sarcoma: a multi-institutional retrospective study from the Japanese clinical oncology group. Human Pathology, 2022, 124, 24-35.	2.0	2
7	Microcystic stromal tumor of the ovary: a recurrent case with somatic CTNNB1 missense mutation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 481, 799-804.	2.8	1
8	Gross mucinous multinodular appearance aids in the identification of ovarian metastases in low-grade appendiceal mucinous neoplasms during intraoperative consultation. Annals of Diagnostic Pathology, 2021, 50, 151641.	1.3	3
9	Diagnostic Discordance in Intraoperative Frozen Section Diagnosis of Ovarian Tumors: A Literature Review and Analysis of 871 Cases Treated at a Japanese Cancer Center. International Journal of Surgical Pathology, 2021, 29, 30-38.	0.8	18
10	Gastric-type cervical adenocarcinoma with squamous differentiation: buried in adenosquamous carcinomas?. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 407-412.	2.8	2
11	Magnetic resonance imaging findings in 11 cases of dedifferentiated endometrial carcinoma of the uterus. Japanese Journal of Radiology, 2021, 39, 477-486.	2.4	1
12	Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1161-1171.	2.8	16
13	Pelvic seromucinous borderline tumor 26Âyears after ovarian seromucinous borderline tumor managed with post-treatment estrogen replacement therapy. Gynecologic Oncology Reports, 2021, 35, 100692.	0.6	2
14	Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center. Taiwanese Journal of Obstetrics and Gynecology, 2021, 60, 238-244.	1.3	3
15	Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients. Pathology and Oncology Research, 2021, 27, 598550.	1.9	7
16	Comparative Analysis of Genetic Alterations, HPV-Status, and PD-L1 Expression in Neuroendocrine Carcinomas of the Cervix. Cancers, 2021, 13, 1215.	3.7	13
17	Distribution of genetic alterations in high-risk early-stage cervical cancer patients treated with postoperative radiation therapy. Scientific Reports, 2021, 11, 10567.	3.3	7
18	On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. Redox Biology, 2021, 41, 101926.	9.0	20

Hiroshi Yoshida

#	Article	IF	CITATIONS
19	Requirements for implementation of artificial intelligence in the practice of gastrointestinal pathology. World Journal of Gastroenterology, 2021, 27, 2818-2833.	3.3	17
20	TP53 mutants and non-HPV16/18 genotypes are poor prognostic factors for concurrent chemoradiotherapy in locally advanced cervical cancer. Scientific Reports, 2021, 11, 19261.	3.3	14
21	Human epidermal growth factor receptor 2 targeted therapy in endometrial cancer: Clinical and pathological perspectives. World Journal of Clinical Oncology, 2021, 12, 868-881.	2.3	8
22	Molecular Pathology of Human Papilloma Virus-Negative Cervical Cancers. Cancers, 2021, 13, 6351.	3.7	15
23	A case of cervical adenocarcinoma arising from endometriosis in the absence of human papilloma virus infection. Journal of Obstetrics and Gynaecology Research, 2020, 46, 536-541.	1.3	7
24	Genomic alterations in STK11 can predict clinical outcomes in cervical cancer patients. Gynecologic Oncology, 2020, 156, 203-210.	1.4	27
25	Characteristics and prognostic significance of incidentally detected cancer cells in uterine specimens of patients with pelvic high \widehat{s} rade serous carcinoma. Cytopathology, 2020, 31, 122-129.	0.7	2
26	Details of human epidermal growth factor receptor 2 status in 454 cases of biliary tract cancer. Human Pathology, 2020, 105, 9-19.	2.0	15
27	Novel classification of ovarian metastases originating from colorectal cancer by radiological imaging and macroscopic appearance. International Journal of Clinical Oncology, 2020, 25, 1663-1671.	2.2	7
28	Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 429-436.	2.8	0
29	Efficacy of ascitic fluid cell block for diagnosing primary ovarian, peritoneal, and tubal cancer in patients with peritoneal carcinomatosis with ascites. Gynecologic Oncology, 2020, 157, 398-404.	1.4	5
30	Clinicopathological and molecular correlations in traditional serrated adenoma. Journal of Gastroenterology, 2020, 55, 418-427.	5.1	15
31	Impact of blurs on machine-learning aided digital pathology image analysis. Artificial Intelligence in Cancer, 2020, 1, 31-38.	0.1	3
32	Prognostic impact of intraoperative peritoneal cytology in interval debulking surgery for pelvic highâ€grade serous carcinoma. Cancer Medicine, 2019, 8, 4598-4604.	2.8	6
33	An Ex-Vivo Culture System of Ovarian Cancer Faithfully Recapitulating the Pathological Features of Primary Tumors. Cells, 2019, 8, 644.	4.1	9
34	Malignant struma ovarii presenting with follicular carcinoma: A case report with molecular analysis. Gynecologic Oncology Reports, 2019, 30, 100498.	0.6	11
35	Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data. Gynecologic Oncology, 2019, 154, 441-448.	1.4	74
36	Primary Clear Cell Adenocarcinoma of the Vulva: A Case Study With Mutation Analysis and Literature Review. International Journal of Surgical Pathology, 2019, 27, 792-797.	0.8	7

Hiroshi Yoshida

#	Article	IF	CITATIONS
37	Feasibility and utility of a panel testing for 114 cancerâ€associated genes in a clinical setting: A hospitalâ€based study. Cancer Science, 2019, 110, 1480-1490.	3.9	238
38	Endometrial cancer arising after complete remission of uterine malignant lymphoma: A case report and mutation analysis. Gynecologic Oncology Reports, 2019, 28, 50-53.	0.6	2
39	Metachronous occurrence of two different histological subtypes of endometriosis-related neoplasms. Gynecologic Oncology Reports, 2019, 27, 42-45.	0.6	5
40	Prognostic factors of synchronous endometrial and ovarian endometrioid carcinoma. Journal of Gynecologic Oncology, 2019, 30, e7.	2.2	16
41	Uterine adenosarcoma in Japan: Clinicopathologic features, diagnosis and management. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 318-325.	1.1	10
42	Automated histological classification of whole-slide images of gastric biopsy specimens. Gastric Cancer, 2018, 21, 249-257.	5.3	80
43	Incidental lymphangioleiomyomatosis in the lymph nodes of gynecologic surgical specimens. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2018, 231, 93-97.	1.1	5
44	Prognostic factors for patients with early-stage uterine serous carcinoma without adjuvant therapy. Journal of Gynecologic Oncology, 2018, 29, e34.	2.2	22
45	Reappraisal of the genetic heterogeneity of sessile serrated adenoma/polyp. Histopathology, 2018, 73, 672-680.	2.9	9
46	Infrequent mismatch repair protein loss in gallbladder cancer patients in Japan. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 109-112.	2.8	2
47	WNT Pathway Gene Mutations Are Associated With the Presence of Dysplasia in Colorectal Sessile Serrated Adenoma/Polyps. American Journal of Surgical Pathology, 2017, 41, 1188-1197.	3.7	61
48	Mismatch repair deficiency commonly precedes adenoma formation in Lynch Syndrome-Associated colorectal tumorigenesis. Modern Pathology, 2017, 30, 1144-1151.	5.5	56
49	Automated histological classification of whole slide images of colorectal biopsy specimens. Oncotarget, 2017, 8, 90719-90729.	1.8	32
50	Frequent <i>PTPRK-RSPO3</i> fusions and <i>RNF43</i> mutations in colorectal traditional serrated adenoma. Journal of Pathology, 2016, 239, 133-138.	4.5	99
51	Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials. Molecular Cancer, 2016, 15, 73.	19.2	47
52	A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 431-439.	2.8	33
53	Comparison of HER2 status between surgically resected specimens and matched biopsy specimens of gastric intestinal-type adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 145-154.	2.8	47